<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36662">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01703221</url>
  </required_header>
  <id_info>
    <org_study_id>3102-020</org_study_id>
    <secondary_id>132239</secondary_id>
    <nct_id>NCT01703221</nct_id>
  </id_info>
  <brief_title>MK-3102 Phase III Clinical Trial - Placebo- and Sitagliptin-controlled Monotherapy Study in Japanese Participants With Type 2 Diabetes Mellitis (MK-3102-020)</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Placebo- and Sitagliptin-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitis Who Have Inadequate Glycemic Control on Diet/Exercise Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of MK-3102 25 mg weekly (as monotherapy)
      compared with sitagliptin 50 mg daily and placebo, and the long term safety (up to 52 weeks)
      of MK-3102 25 mg weekly. The primary hypotheses are that after 24 weeks 1) MK-3102 25 mg
      weekly provides a greater reduction from baseline in glycosylated hemoglobin (HbA1c)
      compared with placebo, and 2) the mean change from baseline in HbA1c in participants treated
      with MK-3102 25 mg weekly is non-inferior compared with that in participants treated with
      sitagliptin 50 mg daily.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline for hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced at least one adverse event</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced at least one adverse event</measure>
    <time_frame>Up to Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinued from the study due to an adverse event</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinued from the study due to an adverse event</measure>
    <time_frame>Up to Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for 2-hour post meal glucose (PMG)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">414</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MK-3102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-3102 25 mg administered orally once weekly and matching placebo to sitagliptin administered orally once daily for 24 weeks (Phase A), followed by MK-3102 25 mg administered orally once weekly for 28 weeks (Phase B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 50 mg administered orally once daily and matching placebo to MK-3102 administered orally once weekly for 24 weeks (Phase A), followed by MK-3102 25 mg administered orally once weekly for 28 weeks (Phase B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to MK-3102 administered orally once weekly and matching placebo to sitagliptin administered orally once daily for 24 weeks (Phase A), followed by MK-3102 25 mg administered orally once weekly for 28 weeks (Phase B).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3102</intervention_name>
    <description>MK-3102 25 mg capsule administered orally once weekly</description>
    <arm_group_label>MK-3102</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 50 mg tablet administered orally once daily</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>JanuviaÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-3102</intervention_name>
    <description>Matching placebo to MK-3102 25 mg capsule administered orally once weekly</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to sitagliptin</intervention_name>
    <description>Matching placebo to sitagliptin 50 mg tablet administered orally once daily</description>
    <arm_group_label>MK-3102</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has type 2 diabetes mellitus

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or a history of ketoacidosis

          -  History of any of the following medications: thiazolidinediones and/or insulin within
             12 weeks prior to study participation, MK-3102 and/or sitagliptin anytime
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>October 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
